Key facts
- This page summarizes Mark Chin's Form 4 filing for IMARA Inc. (ELVN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 Jun 2022, 20:19.
Mark Chin - 02 Jun 2022 Form 4 Insider Report for IMARA Inc. (ELVN)
- Reporting relationship
- Director
- Issuer ticker
- ELVN
- Reported as of
- 02 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jun 2022, 20:19:10 UTC
- Prior SEC filing
- 25 Apr 2022
- Next SEC filing
- 17 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael P. Gray, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark Chin filed Form 4 for IMARA Inc. (ELVN) on 03 Jun 2022.
Change
- Previous filing in this sequence was filed on 25 Apr 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ELVN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,344,072
- Date
- 02 Jun 2022
- Ownership
- By entities affiliated with Arix Bioscience plc
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELVN
transaction
Derivative
Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +8,500
- Change %
- Price
- $0.000000
- Shares after
- 8,500
- Date
- 02 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,500
- Exercise price
- $1.07
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares are directly beneficially owned by Arix Bioscience Holdings Limited ("Arix Ltd."). Arix Bioscience Plc ("Arix Plc") is the sole owner and parent of Arix Ltd. and may be deemed to indirectly beneficially own the shares held by Arix Ltd. Mr. Chin is a managing director of Arix plc. Each of Arix plc and Mr. Chin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.
Footnote F2
The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant.